rss
Evid Based Med 17:178-179 doi:10.1136/ebmed-2012-100641
  • Therapeutics

In patients with coronary artery disease and heart failure, the addition of coronary-artery bypass grafting to medical therapy has no effect on the overall risk of death from any cause, but assessment of suitability for surgery may predict survival benefit in subgroups

  1. Ting Zhang
  1. Division of Cardiovascular Surgery, University Health Network, Department of Surgery, University of Toronto, Canada
  1. Correspondence to: Terrence M Yau
    4N-470, Toronto General Hospital, 200 Elizabeth Street, ON M5G 2C4, Canada. terry.yau{at}uhn.on.ca

Commentary on:

Context

More than 5.8 million Americans and 500 000 Canadians are currently living with heart failure (HF). The 5-year survival rate is a dismal 40–50%. Coronary artery disease (CAD) is the most common cause of HF, but the role of coronary artery bypass surgery (CABG) in HF has never been definitively established.

Methods

The Surgical Treatment for Ischaemic HF trial aimed to determine whether CABG improves survival in patients with CAD and impaired left ventricular (LV) function (hypothesis 1). A total of 1212 adults with CAD amenable to CABG and left ventricular ejection fraction (LVEF) ≤35% were enrolled from 127 sites across 26 countries. The original intended enrolment of 2000 patients was revised due to slow enrolment rates, necessitating an increase in the duration of follow-up from …

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBM.
View free sample issue >>


Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article